Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)

After having discussions on how to progress this topic, we are now able to provide an update. I can confirm that we are proceeding with an HST evaluation for sebelipase. This work will target a new decision problem, for the Wolman’s disease population. We will plan this topic into work programme to re-start as soon as possible. We will provide further details on the timings and process once finalised.